UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 77

Sortiert nach

Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants

Molecular therapy, 2016-09, Vol.24 (9), p.1675-1685

2016

Volltextzugriff (PDF)

Emerging Biomarkers for Immunotherapy in Glioblastoma

Cancers, 2022-04, Vol.14 (8), p.1940

2022

Volltextzugriff (PDF)

Long-term surviving cancer patients as a source of therapeutic TCR

Cancer Immunology, Immunotherapy, 2020-05, Vol.69 (5), p.859-865

2020

Volltextzugriff (PDF)

Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001

Oncoimmunology, 2012-08, Vol.1 (5), p.670-686

2012

Volltextzugriff (PDF)

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma

Cancer Immunology, Immunotherapy, 2013-09, Vol.62 (9), p.1499-1509

2013

Volltextzugriff (PDF)

A TCR-based Chimeric Antigen Receptor

Scientific reports, 2017-09, Vol.7 (1), p.10713-10, Article 10713

2017

Volltextzugriff (PDF)

A Spheroid Killing Assay by CAR T Cells

Journal of visualized experiments, 2018-12 (142)

2018

Volltextzugriff (PDF)

ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma

Nature communications, 2023-06, Vol.14 (1), p.3375-3375, Article 3375

2023

Volltextzugriff (PDF)

Artesunate shows potent anti-tumor activity in B-cell lymphoma

Journal of hematology and oncology, 2018-02, Vol.11 (1), p.23-12, Article 23

2018

Volltextzugriff (PDF)

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer

Frontiers in immunology, 2020-11, Vol.11, p.572172-572172

2020

Volltextzugriff (PDF)

Sympathetic improvement of cancer vaccine efficacy

Human vaccines & immunotherapeutics, 2020-08, Vol.16 (8), p.1888-1890

2020

Volltextzugriff (PDF)

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

Journal of translational medicine, 2022-09, Vol.20 (1), p.1-419, Article 419

2022

Volltextzugriff (PDF)

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors

Oncoimmunology, 2021-01, Vol.10 (1), p.1936757-1936757

2021

Volltextzugriff (PDF)

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial

Frontiers in immunology, 2021-05, Vol.12, p.663865-663865

2021

Volltextzugriff (PDF)

Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity

Oncoimmunology, 2019-01, Vol.8 (3), p.1558663-1558663

2019

Volltextzugriff (PDF)

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

Journal for immunotherapy of cancer, 2022-05, Vol.10 (5), p.e004345

2022

Volltextzugriff (PDF)

A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)

Frontiers in oncology, 2022-11, Vol.12, p.1031232-1031232

2022

Volltextzugriff (PDF)

P611: CD37 AS A MOLECULAR TARGET FOR CAR‐T CELLS AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA

HemaSphere, 2023-08, Vol.7 (S3), p.e69513e8-n/a

2023

Volltextzugriff (PDF)

Determination of CAR T cell metabolism in an optimized protocol

Frontiers in bioengineering and biotechnology, 2023, Vol.11, p.1207576-1207576

2023

Volltextzugriff (PDF)

Colorectal cysts as a validating tool for CAR therapy

BMC biotechnology, 2020-06, Vol.20 (1), p.1-30, Article 30

2020

Volltextzugriff (PDF)

Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei

Journal for immunotherapy of cancer, 2021-10, Vol.9 (10), p.e003109

2021

Volltextzugriff (PDF)

Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16

Journal for immunotherapy of cancer, 2024-04, Vol.12 (4), p.e008179

2024

Volltextzugriff (PDF)

Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer

Journal of personalized medicine, 2021-06, Vol.11 (7), p.605

2021

Volltextzugriff (PDF)

382 The synthetic long peptide cancer vaccine UV1 in combination with ipilimumab induces a CD4+ Th1 anti-hTERT immune response and an inflammatory tumor microenvironment in patients with melanoma

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A416-A416

2021

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(75)

Publikationsform

Artikel
(76)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants

Emerging Biomarkers for Immunotherapy in Glioblastoma

Long-term surviving cancer patients as a source of therapeutic TCR

Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma

A TCR-based Chimeric Antigen Receptor

A Spheroid Killing Assay by CAR T Cells

ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma

Artesunate shows potent anti-tumor activity in B-cell lymphoma

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer

Sympathetic improvement of cancer vaccine efficacy

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial

Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)

CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies

P611: CD37 AS A MOLECULAR TARGET FOR CAR‐T CELLS AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA

Determination of CAR T cell metabolism in an optimized protocol

Colorectal cysts as a validating tool for CAR therapy

Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei

Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16

Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer

382 The synthetic long peptide cancer vaccine UV1 in combination with ipilimumab induces a CD4+ Th1 anti-hTERT immune response and an inflammatory tumor microenvironment in patients with melanoma

Suchergebnisse filtern